Design and evaluation of controlled-release niosomes and discomes for naltrexone hydrochloride ocular delivery

Journal of Pharmaceutical Sciences

Volumn 100, Issue 5, 2011, Pages 1833-1846

  Abdelkader, Hamdy ^a,c   Ismail, Sayed ^b   Kamal, Amal ^c   Alany, Raid G ^a,d  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

^b Assiut University   (Egypt)

^c Minia University   (Egypt)

^d KINGSTON UNIVERSITY   (United Kingdom)

Author keywords

Bilayer; Calorimetry (DSC); Controlled delivery; Diabetic keratopathy; Discomes; Formulation; Liposomes; Naltrexone hydrochloride; Niosomes

Indexed keywords

CHOLIC ACID; DICETYL PHOSPHATE; DISCOME; DRUG CARRIER; NALTREXONE; NIOSOME; OCTADECYLAMINE; POLY 24 OXYETHYLENE CHOLESTERYL ETHER; SORBITAN STEARATE; SURFACTANT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BILAYER MEMBRANE; CONTROLLED DRUG RELEASE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; IN VITRO STUDY; NONHUMAN; TOPICAL DRUG ADMINISTRATION;

EID: 79952252661     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22422     Document Type: Article

References (81)

1. Macha S, Hughes PM, Mitra AK. 2003. Overview of ocular drug delivery. In Ophthalmic drug delivery systems; Mitra AK, Ed. 2nd ed.New York: Marcel Dekker, pp 1-11.
2. Lang JC, Roehrs RE, Rodeheaver DP, Missel PJ, Jani R, Chowhan MA. 2002. Design and evaluation of ophthalmic pharmaceutical products. In Modern pharmaceutics; Banker GS, Rhodes CT, Eds. New York: Marcel Dekker, pp 626-717.
3. Urtti A. 2006. Ocular drug delivery. Adv Drug Del Rev 58:1129-1130.
4. Kaur IP, Garg A, Aggarwal D. 2004. Vesicular systems in ocular drug delivery: An overview. Int J Pharm 269: 1-14.
5. Kaur IP, Rana C, Singh H. 2008. Development of effective ocular preparations of antifungal agents. J Ocul Pharmacol Ther 24:481-493.
6. Kaur IP, Smitha R. 2002. Penetration enhancers and ocular bioadhesives: Two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm 28:353-369.
7. Alany RG, Rades T, Nicoll J, Tucker IG, Davies NM. 2006. W/O microemulsions for ocular delivery: Evaluation of ocular irritation and precorneal retention. J Control Release 111:145-152.
8. Zimmer AK, Kreuter J. 1991. Studies on the transport pathway of PBCA nanoparticles in ocular tissues. J Microencapsul 8:497-504.
9. Miyazaki S, Suzuki S, Kawasaki N, Endo K, Takahashi A, Attwood D. 2001. In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int J Pharm 229:29-36.
10. Kaiserman I, Kaiserman N, Nakar S, Vinker S. 2005. Dry eye in diabetic patients. Am J Ophthalmology 139:498-503.
11. Dogru M, Katakami C, Inoue M. 2001. Tear function and ocular surface changes in noninsulin-dependent diabetes mellitus. Ophthalmology 108:586-592.
12. Akinci A, Cetinkaya E, Aycan Z. 2007. Dry eye syndrome in diabetic children. Eur J Ophthalmology 17:873-878.
13. Gregoriadis G, Florence AT. 1993. Liposomes in drug delivery: Clinical, diagnostic and ophthalmic potential Drugs 45:15-28.
14. Le Bourlias CA, Treupel-Acar L, Rhodes CT, Sado PA, Leverge R. 1995. New ophthalmic drug delivery systems. Drug Dev Ind Pharm 21:19-59.
15. El-Gazayerly ON, Hikal AH. 1997. Preparation and evaluation of acetazolamide liposomes as ocular delivery systems. Int J Pharm 158:121-127.
16. Uchegbu IF, Vyas SP. 1998. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 172: 33-70.
17. Clarymist. Savant Distribution, UK. 9th October 2010
18. Saettone MF, Perini G, Carafa M, Santucci E, Alhaique F. 1996. Non-ionic surfactant vesicles as ophthalmic carriers for cyclopentolate. A preliminary evaluation. STP Pharma Sci 6:94-98.
19. Vyas SP, Mysore N, Jaittley V, Venkatesan N. 1998. Discoidal niosome based controlled ocular delivery of Timolol maleate.Pharmazie 53:466-469.
20. Aggarwal D, Garg A, Kaur IP. 2004. Development of a topical niosomal preparation of acetazolamide: Preparation and evaluation. J Pharm Pharmacol 56:1509-1517.
21. Abdelbary G, El-gendy N. 2008. Niosome-encapsulated gentamicin for ophthalmic controlled delivery AAPS PharmSciTech 9:740-747.
22. Nasr M, Mansour S, Mortada ND, Elshamy AA. 2008. Vesicular aceclofenac systems: A comparative study between liposomes and niosomes. J Microencapsul 25:499-512.
23. Fitzgerald P, Hadgraft J, Kreuter J, Wilson CG. 1987. A gamma-scintigraphic evaluation of microparticulate ophthalmic delivery systems: Liposomes and nanoparticles. Int J Pharm 40:81-84.
24. Hathout RM, Mansour S, Mortada ND, Guinedi AS. 2007. Liposomes as an ocular delivery system for acetazolamide: In vitro and in vivo studies. AAPS PharmSciTech 8 (1):E1-E12.
25. Uchegbu IF, Schatzlein AG, Vanlerrberghe G, Morgatini N, Florence AT. 1997. Polyhedral non-ionic surfactant vesicles. J Pharm Pharmacol 49:606-610.
26. Uchegbu IF, Bouwstra JA, Florence AT. 1992. Large disk-shaped structures (Discomes) in non-ionic surfactant vesicles to micelle transitions. J Phys Chem 96:10548-10553.
27. Arunothayanun P, Turton JA, Uchegbu IF, Florence AT. 1999. Preparation and in vitro/in vivo evaluation of luteinizing hormone releasing hormone (LHRH)-loaded polyhedral and spherical/tubular niosomes. J Pharm Sci 88:34-38.
28. Feman SS. 2000. Diabetes and the eye. In Duanes's clinical ophthalmology; Tasman W, Ed. Philadelphia: Lippincott Williams & Wilkins, pp 1-10.
29. Schultz R, Van Horn D, Peters M, Klewin KM, Schutten WH. 1981Diabetic keratopathy. Trans Am Ophthalmol Soc 79:180-199.
30. McLaughlin PJ, Sassani JW, Klocek MS, Zagon IS. 2010. Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: A review. Br Res Bull 81:236-247.
31. Crabtree B. 1984. Review of naltrexone, a long-acting opioate antagonist. Clin Pharm 3:273-279.
32. Fuller MA, Sajatovic M. 2009. Naltrexone. In Drug information handbook for psychiatry; Fuller MA, Sajatovic M, Eds. 7th ed. Hudson, Ohio:Lexi-Comp, pp 1098-1100.
33. Zagon IS, Klocek MS, Sassani JW, McLaughlin PJ. 2009. Dry eye reversal and corneal sensation restoration with topical naltrexone in diabetes mellitus. Arch Ophthalmol 127:1468-1473.
34. Zagon IS, Sassani JW, McLaughlin PJ. 2000. Reepithelialization of the human cornea is regulated by endogenous opioids. Inv Ophthalmol Vis Sci 41(1):73-81.
35. Zagon IS, Sassani JW, Myers RL, McLaughlin PJ. 2007. Naltrexone accelerates healing without compromise of adhesion complexes in normal and diabetic corneal epithelium. Br Res Bull 72:18-24.
36. Bangham AD, Standish MM, Watkins JC. 1965. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13:238-252.
37. Mayer LD, Hope MJ, Cullis PR, Janoff AS. 1985. Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. Biochim Biophys Acta 817:193-196.
38. Kirby CJ, Gregoriadis G. 1984. A simple procedure for preparing liposomes capable of high encapsulation effeciency under mild conditions. In Liposome technology; Gregoriadis G, Ed. Florida: CRC Press, pp 19-27.
39. Hope MJ, Bally MB, Mayer LD, Janoff AS, Cullis PR. 1986. Generation of multilamellar and unilamellar phospholipid vesicles. Chem Phys Lip 40:89-107.
40. Korsmeyer RW, Gurnya R, Doelkera E, Buria P, Peppas NA. 1983. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 15:25-35.
41. Peppas NA. 1985. Analysis of Fickian and non-Fickian drug release from polymers Pharm Acta Helv 60:110-111.
42. Ritger PL, Peppas NA. 1987. A simple equation for the description of solute release III. Coupling of diffusion and relaxation. J Control Release 5:23-36.
43. Mockel JE, Lippold BC. 1993. Zero-order release from hydrocolloid matrices. Pharm Res 90:1066-1070.
44. Schoenwald RD, Huang HS. 1983. Corneal penetration behavior of beta blocking agents I: Physicochemical factors. J Pharm Sci 72:1266-1272.
45. Luepke N. 1985. Hen's egg chorioallantoic membrane test for irritation potential. Food Chem Toxicol 23:287-291.
46. Auerbach R, Kubai L, Knighton D, Folkman J. 1974. A simple procedure for the long-term cultivation of chicken embryos. Dev Biol 41:391-394.
47. Junyaprasert VB, Teeranachaideekul V, Supaperm T. 2008. Effect of charged and non-ionic membrane additives on physichochemical properties and stability of niosomes. AAPS PharmSciTech 9:851-859.
48. Israelachvili JN, Marcelja S, Horn RG. 1980. Physical principles of membrane organization. Quart Rev Biophys 13:121-200.
49. El Maghraby GMM, Williams AC, Barry BW. 2004. Interactions of surfactants (edge activators) and skin penetration enhancers with liposomes. Int J Pharm 276:143161
50. Dimitrijevic D, Lamandin C, Uchegbu IF, Shaw AJ, Florence AT. 1997. The effect of monomers and micellar and vesicular forms of non-ionic surfactants (Solulan C24 and Solulan 16) on caco-2 cell monolayers. J Pharm Pharmacol 49:611-616.
51. Suwakul W, Ongpipattanakul B, Vardhanabhuti N. 2006. Preparation and characterization of propylthiouracil Niosomes. J Liposome Res 16:391-401.
52. Schulz PC, Moya S. 1998. Study of the required HLB for the solubilization of cholesterol in aqueous solution. Colloid Polym Sci 276:87-91.
53. Kim JG, Kim JD. 1991. Vesicle to micelle transitions of egg phosphatidylcholine liposomes induced by nonionic surfactants, poly(oxyethylene) cetyl ethers. J Biochem 110:436-442.
54. Walter A, Vinson PK, Kaplun A, Talmon Y. 1991. Intermediate structures in the cholate-phosphatidylcholine vesiclemicelle transition. Biophys J 60:1315-1325.
55. Ollivon M, Eidelman O, Blumenthal R, Walter A. 1988. Micelle-vesicle transition of egg phosphatidylcholine and octylglucoside. Biochemistry 27:1695-1703.
56. Walter A, Vinson PK, Kaplun A, Talmon Y. 1991. Intermediate structures in the cholate-phosphatidylcholine vesicle-micelle transition. Biophys J 60:1315-1325.
57. Maestrelli F, Gonzalez-Rodriguez M, Rabasco A, Mura P. 2006. Effect of preparation technique on the properties of liposomes encapsulating ketoprofen-cyclodextrin complexes aimed for transdermal delivery. Int J Pharm 312:53-60.
58. Maestrelli F, Capasso G, Gonzalez-Rodriguez M, Rabasco A, Mura P. 2009. Effect of preparation technique on the properties and in vivo efficacy ethosome -loaded benzocaine. J Liposome Res 19:253-260.
59. Szoka F, Papahadjopoulos D. 1978. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci 75:4194-4198.
60. Kirby C, Gregoriadis G. 1984. Dehydration-rehydration vesicles: A simple method for high yield drug entrapment in liposomes. Biotechnology 2:979-984.
61. Cevc G, Blume G, Schatzlein A, Gebauer D, Paul A. 1996. The skin: A pathway for systemic treatment with patches and lipid-based agent carriers. Adv Drug Deliv Rev 18:349-378.
62. Uchegbu IF, Florence AT. 1995. Non-ionic surfactant vesicles (niosomes): Physical and pharmaceutical chemistry. Adv Colloid Interface Sci 58:1-55.
63. Mainardes RM, Urban MC, Cinto PO, Khalil NM, Chaud Mv, Evangelista RC, Gremião MP. 2005. Colloidal carriers for ophthalmic drug delivery. Curr Drug Targets 6:363-371.
64. El Maghraby GMM, Williams AC, B.W.B 2005. Drug interaction and location in liposomes: Correlation with polar surface areas. 292:179-185.
65. Lo YL, Rahman YE. 1995. Protein location in liposomes, a drug carrier: A prediction by differential scanning calorimetry. J Pharm Sci 84:805-814.
66. Papahadjopoulos D, Moscarello M, Eylar EH, Isac T. 1975. Effects of proteins on thermotropic phase transition of phospholipid membranes. Biochim Biophys Acta 401:317-335.
67. Rolland A, Brzokewicz A, Shroot B, Jamoulle JC. 1991. Effect of penetration enhancers on the phase transition of multilamellar liposomes of dipalmitoylphosphatidylcholine. A study by differential scanning calorimetry. Int J Pharm 76:217-224.
68. Abdelkader H, Kamal H, Ismail S, Alany RG. 2010. Preparation of niosomes as an ocular delivery system for naltrexone hydrochloride: Physicochemical characterization. Pharmazie 65: 811-817.
69. Israelachvili JN, Mitchell DJ. 1975. A model for the packing of lipids in bilayer membranes. Biochim Biophys Acta 389:13-19.
70. Khan KA. 1975. The concept of dissolution efficiency. J Pharm Pharmacol 27:48-49.
71. Law SL, Huang KJ, Chiang CH. 2000. Acyclovir-containing liposomes for potential ocular delivery corneal penetration and absorption. J Control Release 63:135-140.
72. Attama AA, Reichl S, Muller-Goymann CC. 2009. Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea. Curr Eye Res 34:698-705.
73. Bayindir ZS, Yuksel N. 2010. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharm Sci 99:2049-2060.
74. Guinedi AS, Mortada ND, Mansour S, Hathout RM. 2005. Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm 306:71-82.
75. Abdelkader H, Abdallah OY, Salem H. 2008. Formulation of controlled-release baclofen matrix tablets II: Influence of some hydrophobic excipients on the release rate and in vitro evaluation. AAPS PharmSciTech 9:675-683.
76. El Maghraby GM. 2010. Self-microemulsifying and microemulsion systems for transdermal delivery of indomethacin: Effect of phase transition. Colloids Surf B Biointerfaces 75:595-600.
77. Schaeffer HE, Krohn DL. 1982. Liposomes in topical drug delivery. Invest Ophthalmol Vis Sci 22:220-227.
78. Lawrence MJ. 2003. Sorbitan esters (sorbitan fatty acid esters). In Handbook of pharmaceutical excipients; Rowe RC, Sheskey PL, Weller PL, Ed. 4th ed. London: Pharmaceutical Press, pp 591-595.
79. Buehler JD. 2003. Cholesterol. In Handbook of pharmaceutical excipients; Rowe RC, Sheskey PL, Weller PL, Ed. 4th ed. London: Pharmaceutical Press, pp 155-157.
80. Kinouchi Y, Takeichi Y, Yata N. 1996. A novel method for the preclinical assessment of rectal irritation. J Pharm Pharmacol 48:310-315.
81. Furrer P, Mayer JM, Plazonnet B, Gurny R. 2002. Ocular tolerance of absorption enhancers in ophthalmic preparations. AAPS PharmSci 4:1-5.